Sen. Grassley’s letter to Amgen regarding FDA access to study data and rebate payments and discounts to physicians

Webp adobestock 309942906
Adobe Stock

Sen. Grassley’s letter to Amgen regarding FDA access to study data and rebate payments and discounts to physicians

The following press release was published by the United States Senate Committee on Finance Chairman's News on Sept. 19, 2007. It is reproduced in full below.

Dear Mr. Sharer:

The United States Senate Committee on Finance (Committee) has jurisdiction over the Medicare and Medicaid programs and, accordingly, a responsibility to the more than 80 million Americans who receive health care coverage under those programs to oversee the proper administration of the programs, including the payment for prescription drugs regulated by the Food and Drug Administration (FDA).

Thank you for the briefing that Amgen Inc. (Amgen) provided my Committee staff on May 24, 2007, in response to my letter to you dated May 16, 2007. Additionally, thank you for your cooperation with the Committee’s request for information related to erythropoiesis-stimulating agents (ESAs).

Source: US Senate Committee on Finance Chairman's News

More News